A decision-tree approach to cost comparison of newborn screening strategies for cystic fibrosis

Pediatrics

Volumn 129, Issue 2, 2012, Pages

  Wells, Janelle ^a   Rosenberg, Marjorie ^a,b   Hoffman, Gary ^c   Anstead, Michael ^d   Farrell, Philip M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WISCONSIN STATE LABORATORY OF HYGIENE   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Costs; Cystic fibrosis; DNA; Immunoreactive trypsinogen; Newborn screening; Sensitivity

Indexed keywords

TRYPSINOGEN;

ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; FOLLOW UP; GENE MUTATION; HEALTH CARE COST; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIMULATION;

EID: 84856551093     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-0096     Document Type: Article

References (49)

1. Crossley JR, Elliott RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet. 1979;1(8114):472-474 (Pubitemid 9127240)
2. Grosse SD, Boyle CA, Botkin JR, et al CDC. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. 2004;53(RR-13):1-36
3. Campbell PW, III, White TB. Newborn screening for cystic fibrosis: an opportunity to improve care and outcomes. J Pediatr. 2005;147(suppl 3):S2-S5 (Pubitemid 41400251)
4. Department of Health and Human Services. Newborn screening: toward a uniform screening panel and system. 70 Federal Register 11247 (2005)
5. Gregg RG, Wilfond BS, Farrell PM, Laxova A, Hassemer D, Mischler EH. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet. 1993;52(3):616-626 (Pubitemid 23311332)
6. Kloosterboer M, Hoffman G, Rock MJ, et al. Clarification of laboratory and clinical variables that influence cystic fibrosis newborn screening with initial analysis of immunoreactive trypsinogen. Pediatrics. 2009;123(2). Available at: www.pediatrics.org/cgi/content/full/123/2/e338
7. Ross LF. Newborn screening for cystic fibrosis: a lesson in public health disparities. J Pediatr. 2008;153(3):308-313
8. Castellani C, Southern KW, Brownlee K, et al. European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros. 2009;8(3):153-173
9. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-1080 (Pubitemid 19231815)
10. Lee DS, Rosenberg MA, Peterson A, et al. Analysis of the costs of diagnosing cystic fibrosis with a newborn screening program. J Pediatr. 2003;142(6):617-623 (Pubitemid 36737163)
11. Rosenberg MA, Farrell PM. Assessing the cost of cystic fibrosis diagnosis and treatment. J Pediatr. 2005;147(suppl 3):S101-S105 (Pubitemid 41400269)
12. van den Akker-van Marle ME, Dankert HM, Verkerk PH, Dankert-Roelse JE. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis. Pediatrics. 2006;118(3):896-905 (Pubitemid 46090029)
13. Sims EJ, Clark A, McCormick J, Mehta G, Connett G, Mehta A; United Kingdom Cystic Fibrosis Database Steering Committee. Cystic fibrosis diagnosed after 2 months of age leads to worse outcomes and requires more therapy. Pediatrics. 2007;119(1):19-28 (Pubitemid 46397838)
14. Sims EJ, Mugford M, Clark A, et al UK Cystic Fibrosis Database Steering Committee. Economic implications of newborn screening for cystic fibrosis: a cost of illness retrospective cohort study. Lancet. 2007;369(9568):1187-1195 (Pubitemid 46546435)
15. Sekhar DL, Wang L, Hollenbeak CS, Widome MD, Paul IM. A cost-effectiveness analysis of screening urine dipsticks in well-child care. Pediatrics. 2010;125(4):660-663
16. Simpson N, Anderson R, Sassi F, et al. The cost-effectiveness of neonatal screening for cystic fibrosis: an analysis of alternative scenarios using a decision model. Cost Eff Resour Alloc. 2005;3:8
17. Mandelblatt J, Freeman H, Winczewski D, et al. The costs and effects of cervical and breast cancer screening in a public hospital emergency room. The Cancer Control Center of Harlem. Am J Public Health. 1997;87(7):1182-1189 (Pubitemid 27311413)
18. Kosorok MR, Wei WH, Farrell PM. The incidence of cystic fibrosis. Stat Med. 1996;15(5):449-462 (Pubitemid 26073580)
19. Hale JE, Parad RB, Comeau AM. Newborn screening showing decreasing incidence of cystic fibrosis. N Engl J Med. 2008;358(9):973-974 (Pubitemid 351397113)
20. Castellani C, Picci L, Tamanini A, Girardi P, Rizzotti P, Assael BM. Association between carrier screening and incidence of cystic fibrosis. JAMA. 2009;302(23):2573-2579
21. Massie J, Curnow L, Gaffney L, Carlin J, Francis I. Declining prevalence of cystic fibrosis since the introduction of newborn screening. Arch Dis Child. 2010;95(7):531-533
22. Grody WW, Cutting GR, Klinger KW, Richards CS, Watson MS, Desnick RJ; Subcommittee on Cystic Fibrosis Screening, Accreditation of Genetic Services Committee, ACMG. American College of Medical Genetics. Laboratory standards and guidelines for population-based cystic fibrosis carrier screening. Genet Med. 2001;3(2):149-154
23. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113(6):1573-1581 (Pubitemid 38697961)
24. Southern KW, Munck A, Pollitt R, et al; ECFS CF Neonatal Screening Working Group. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros. 2007;6(1):57-65 (Pubitemid 46029890)
25. Farrell PM, Joffe S, Foley L, Canny GJ, Mayne P, Rosenberg M. Diagnosis of cystic fibrosis in the Republic of Ireland: epidemiology and costs. Ir Med J. 2007;100(8):557-560
26. Sontag MK, Hammond KB, Zielenski J, Wagener JS, Accurso FJ. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes. J Pediatr. 2005;147(suppl 3):S83-S88 (Pubitemid 41400265)
27. Hammond KB, Abman SH, Sokol RJ, Accurso FJ. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med. 1991;325(11):769-774
28. Henry RL, Boulton TJ, Roddick LG. False negative results on newborn screening for cystic fibrosis. J Paediatr Child Health. 1990;26(3):150-151 (Pubitemid 20240920)
29. Hassemer DJ, Laessig RH, Hoffman GL, Farrell PM. Laboratory quality control issues related to screening newborns for cystic fibrosis using immunoreactive trypsin. Pediatr Pulmonol Suppl. 1991;7:76-83
30. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: a comparison of two strategies for case detection in 1.2 million babies. J Pediatr. 1995;127(6):965-970 (Pubitemid 26003294)
31. Rock MJ, Mischler EH, Farrell PM, et al. Newborn screening for cystic fibrosis is complicated by age-related decline in immunoreactive trypsinogen levels. Pediatrics. 1990;85(6):1001-1007 (Pubitemid 20184720)
32. Padoan R, Genoni S, Moretti E, Seia M, Giunta A, Corbetta C. Genetic and clinical features of false-negative infants in a neonatal screening programme for cystic fibrosis. Acta Paediatr. 2002;91(1):82-87 (Pubitemid 34151226)
33. Comeau AM, Parad RB, Dorkin HL, et al. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections. Pediatrics. 2004;113(6):1573-1581 (Pubitemid 38697961)
34. Gregg RG, Simantel A, Farrell PM, et al. Newborn screening for cystic fibrosis in Wisconsin: comparison of biochemical and molecular methods. Pediatrics. 1997;99(6):819-824 (Pubitemid 27231354)
35. Collaco JM, Panny SR, Hamosh A, Mogayzel PJ Jr, False negative cystic fibrosis newborn screen. Clin Pediatr (Phila). 2010;49(3):214-216
36. Comeau AM, Parad R, Gerstle R, et al. Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result. J Pediatr. 2005;147(suppl 3):S98-S100 (Pubitemid 41400268)
37. Farrell PM. Improving the health of patients with cystic fibrosis through newborn screening. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Adv Pediatr. 2000;47:79-115
38. Rock MJ, Hoffman G, Laessig RH, Kopish GJ, Litsheim TJ, Farrell PM. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing. J Pediatr. 2005;147(suppl 3):S73-S77 (Pubitemid 41400263)
39. Farrell PM. The meaning of "early" diagnosis in a new era of cystic fibrosis care. Pediatrics. 2007;119(1):156-157 (Pubitemid 46397858)
40. Chatfield S, Owen G, Ryley HC, et al. Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child. 1991;66(1 Spec No):29-33
41. Farrell PM, Kosorok MR, Rock MJ, et al Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Pediatrics. 2001;107(1):1-13 (Pubitemid 32055408)
42. Rosenfeld M. Overview of published evidence on outcomes with early diagnosis from large US observational studies. J Pediatr. 2005;147(suppl 3):S11-S14 (Pubitemid 41400252)
43. Koscik RL, Lai HJ, Laxova A, et al. Preventing early, prolonged vitamin E deficiency: an opportunity for better cognitive outcomes via early diagnosis through neonatal screening. J Pediatr. 2005;147(suppl 3):S51-S56 (Pubitemid 41403280)
44. Lai HJ, Cheng Y, Farrell PM. The survival advantage of patients with cystic fibrosis diagnosed through neonatal screening: evidence from the United States Cystic Fibrosis Foundation registry data. J Pediatr. 2005;147(suppl 3):S57-S63 (Pubitemid 41400260)
45. Farrell PM, Lai HJ, Li Z, et al. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! J Pediatr. 2005;147(suppl 3):S30-S36 (Pubitemid 41400256)
46. Grosse SD, Rosenfeld M, Devine OJ, Lai HJ, Farrell PM. Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr. 2006;149(3):362-366 (Pubitemid 44308429)
47. Legrys VA, McColley SA, Li Z, Farrell PM. The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. J Pediatr. 2010;157(6):1035-1037
48. Baker MW, Groose M, Hoffman G, Rock M, Levy H, Farrell PM. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros. 2011;10(4):278-281
49. Fost N, Farrell PM. A prospective randomized trial of early diagnosis and treatment of cystic fibrosis: a unique ethical dilemma. Clin Res. 1989;37(3):495-500 (Pubitemid 19214804)